A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Acronyms DREAM
- Sponsors Q-Med
- 09 Dec 2019 Status changed from active, no longer recruiting to completed.
- 11 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2018 New trial record